Thursday, October 15, 2026

First BanCorp. New And 3 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

ViaNews Editorial Team

December 24, 2020

First BanCorp. New And 3 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

Here is a list of stocks with an above 10% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?

1. First BanCorp. New

25.6% sales growth and 4% return on equity

First BanCorp.

First BanCorp. New's sales growth this year is expected to be 13.9% and 20.2% for next year.

Year-on-year quarterly revenue growth declined by 16.9%, now sitting on 490.06M for the twelve trailing months.

First BanCorp. New's sales growth for the next quarter is 25.6%. The company's growth estimates for the present quarter and the next is 10.5% and 833.3%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 4%.

First BanCorp. New's Stock Yearly Top and Bottom Value

First BanCorp. New's stock is valued at $8.90 at 04:22 EST, way under its 52-week high of $10.82 and way above its 52-week low of $3.50.

First BanCorp. New's Moving Average

First BanCorp. New's worth is higher than its 50-day moving average of $8.15 and way above its 200-day moving average of $6.32.

2. EPAM Systems, Inc.

13.9% sales growth and 18.86% return on equity

EPAM Systems, Inc. provides digital platform engineering and software development services in North America, Europe, Armenia, Belarus, Kazakhstan, Russia, Ukraine, Asia, and Australia.

EPAM Systems, Inc.'s sales growth this year is anticipated to be 15.1% and 21.6% for next year.

Year-on-year quarterly revenue growth grew by 10.9%, now sitting on 2.57B for the twelve trailing months.

EPAM Systems, Inc.'s sales growth for the next quarter is 13.9%. The company's growth estimates for the present quarter and the next is 13.2% and 17.5%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 18.86%.

EPAM Systems, Inc.'s Stock Yearly Top and Bottom Value

EPAM Systems, Inc.'s stock is valued at $346.53 at 04:22 EST, below its 52-week high of $359.39 and way higher than its 52-week low of $151.97.

EPAM Systems, Inc.'s Moving Average

EPAM Systems, Inc.'s value is above its 50-day moving average of $326.99 and way higher than its 200-day moving average of $302.82.

3. HCI Group, Inc.

8.6% sales growth and 16.31% return on equity

HCI Group, Inc. engages in the property and casualty insurance, reinsurance, real estate, and information technology businesses in Florida.

HCI Group, Inc.'s sales growth this year is anticipated to be 27.7% and a negative 8.4% for next year.

Year-on-year quarterly revenue growth grew by 11.8%, now sitting on 266.39M for the twelve trailing months.

HCI Group, Inc.'s sales growth for the next quarter is 8.6%. The company's growth estimates for the present quarter and the next is a negative 39.5% and 3.7%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 16.31%.

HCI Group, Inc.'s Stock Yearly Top and Bottom Value

HCI Group, Inc.'s stock is valued at $52.59 at 04:22 EST, way under its 52-week high of $62.93 and way higher than its 52-week low of $31.61.

HCI Group, Inc.'s Moving Average

HCI Group, Inc.'s value is above its 50-day moving average of $51.71 and above its 200-day moving average of $49.82.

4. MGP Ingredients, Inc.

17.9% sales growth and 17.67% return on equity

MGP Ingredients, Inc., together with its subsidiaries, produces and supplies distilled spirits, and specialty wheat proteins and starch food ingredients.

MGP Ingredients, Inc.'s sales growth this year is anticipated to be 8.9% and 6.5% for next year.

Year-on-year quarterly revenue growth grew by 13.5%, now sitting on 387.07M for the twelve trailing months.

MGP Ingredients, Inc.'s sales growth for the next quarter is 17.9%. The company's growth estimates for the current quarter and the next is a negative 18.4% and 1.6%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 17.67%.

MGP Ingredients, Inc.'s Stock Yearly Top and Bottom Value

MGP Ingredients, Inc.'s stock is valued at $46.85 at 04:22 EST, way below its 52-week high of $53.33 and way above its 52-week low of $21.64.

MGP Ingredients, Inc.'s Moving Average

MGP Ingredients, Inc.'s worth is higher than its 50-day moving average of $43.59 and way higher than its 200-day moving average of $39.39.

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com